Lassa fever future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lassa fever}} | {{Lassa fever}} | ||
{{CMG}} | {{CMG}}; {{Ammu}} | ||
==Overview== | ==Overview== | ||
Researchers at the [[USAMRIID]] facility, where military [[biologist]]s study [[infectious disease]]s, have a promising [[vaccine]] candidate. They have developed a [[Virus#Replication|replication]]-competent [[vaccine]] against Lassa virus based on [[recombinant]] vesicular [[stomatitis]] [[Vesicular stomatitis virus|virus]] [[vector]]s expressing the Lassa virus [[glycoprotein]]. After a single [[Intramuscular|intramuscular injection]], test primates have survived lethal challenge, while showing no clinical [[symptom]]s.<ref>{{cite journal |author=Geisbert TW, Jones S, Fritz EA, ''et al'' |title=Development of a new vaccine for the prevention of Lassa fever |journal=PLoS Med. |volume=2 |issue=6 |pages=e183 |year=2005 |pmid=15971954 |doi=10.1371/journal.pmed.0020183}}</ref> | Researchers at the [[USAMRIID]] facility, where military [[biologist]]s study [[infectious disease]]s, have a promising [[vaccine]] candidate. They have developed a [[Virus#Replication|replication]]-competent [[vaccine]] against Lassa virus based on [[recombinant]] vesicular [[stomatitis]] [[Vesicular stomatitis virus|virus]] [[vector]]s expressing the Lassa virus [[glycoprotein]]. After a single [[Intramuscular|intramuscular injection]], test primates have survived lethal challenge, while showing no clinical [[symptom]]s.<ref>{{cite journal |author=Geisbert TW, Jones S, Fritz EA, ''et al'' |title=Development of a new vaccine for the prevention of Lassa fever |journal=PLoS Med. |volume=2 |issue=6 |pages=e183 |year=2005 |pmid=15971954 |doi=10.1371/journal.pmed.0020183}}</ref> | ||
| Line 10: | Line 8: | ||
| url = http://www.siga.com/press/051507.html | | url = http://www.siga.com/press/051507.html | ||
| title = SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193}}</ref> | | title = SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193}}</ref> | ||
==Future Research== | |||
* Studies are being conducted to improve the following aspects<ref name="pmidPMID: 18241935">{{cite journal| author=Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A et al.| title=New opportunities for field research on the pathogenesis and treatment of Lassa fever. | journal=Antiviral Res | year= 2008 | volume= 78 | issue= 1 | pages= 103-15 | pmid=PMID: 18241935 | doi=10.1016/j.antiviral.2007.11.003 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18241935 }} </ref>. | |||
:* Efficacy of the supportive treatment. | |||
::* Specific studies for early goal directed therapy. | |||
:* Optimizing [[Ribavirin]] therapy | |||
::* Check whether shorter duration would be helpful. | |||
::* Evaluation of oral [[ribavirin]] for post exposure prophylaxis. | |||
:* Testing efficacy of new anti-arenavirus drugs. | |||
::* Small [[interfering RNAs]]. | |||
::* Novel [[nucleoside]] analogs. | |||
:* Testing efficacy of non-arenavirus-specific drugs. | |||
::* [[Interferon]] alfacon-1. | |||
::* Recombinant activated [[protein C]]. | |||
::* Vaccines with recombinant and attenuated viruses, DNA vaccines, alphavirus replicons. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
Revision as of 09:50, 1 June 2015
|
Lassa fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lassa fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Lassa fever future or investigational therapies |
|
Risk calculators and risk factors for Lassa fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ammu Susheela, M.D. [2]
Overview
Researchers at the USAMRIID facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a replication-competent vaccine against Lassa virus based on recombinant vesicular stomatitis virus vectors expressing the Lassa virus glycoprotein. After a single intramuscular injection, test primates have survived lethal challenge, while showing no clinical symptoms.[1]
Siga Technologies is developing an antiviral drug that has been shown effective in treating experimentally infected guinea pigs. In a study conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), treatment with ST-193 once a day for 14 days resulted in significant reduction in mortality (71% of the animals survived at the low dose), whereas all untreated animals and those treated with ribavirin died within 20 days of the infection.[2]
Future Research
- Studies are being conducted to improve the following aspects[3].
- Efficacy of the supportive treatment.
- Specific studies for early goal directed therapy.
- Optimizing Ribavirin therapy
- Check whether shorter duration would be helpful.
- Evaluation of oral ribavirin for post exposure prophylaxis.
- Testing efficacy of new anti-arenavirus drugs.
- Small interfering RNAs.
- Novel nucleoside analogs.
- Testing efficacy of non-arenavirus-specific drugs.
- Interferon alfacon-1.
- Recombinant activated protein C.
- Vaccines with recombinant and attenuated viruses, DNA vaccines, alphavirus replicons.
References
- ↑ Geisbert TW, Jones S, Fritz EA; et al. (2005). "Development of a new vaccine for the prevention of Lassa fever". PLoS Med. 2 (6): e183. doi:10.1371/journal.pmed.0020183. PMID 15971954.
- ↑ "SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193" (Press release).
- ↑ Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A; et al. (2008). "New opportunities for field research on the pathogenesis and treatment of Lassa fever". Antiviral Res. 78 (1): 103–15. doi:10.1016/j.antiviral.2007.11.003. PMID 18241935 PMID: 18241935 Check
|pmid=value (help).